Anixa Biosciences Share Price Today

Anixa Biosciences to present ovarian cancer CAR-T data at ESMO congress

Anixa Biosciences will present Phase 1 ovarian cancer CAR-T trial data at ESMO Congress in London on December 14, 2026. Fifth cohort completed with patients receiving 1x10⁷ CAR-positive cells/kg, a 100-fold increase over initial doses. No dose-limiting toxicities observed; four patients survived more than one year post-treatment. Next phase involves sixth cohort at 1x10⁸ CAR-positive cells/kg, representing a 1,000-fold increase over starting doses.

Anixa CAR-T patient shows stable disease after 90 days in ovarian cancer trial

First stable disease response recorded in Anixa's Phase 1 ovarian cancer trial. Patient treated in fifth cohort received highest dose of 1×10⁷ CAR-positive cells/kg. Four patients have surpassed one year of survival with durations up to 28 months. No dose-limiting toxicities observed across any cohort to date.

Anixa Biosciences secures Australian patent for breast cancer vaccine through 2040

IP Australia issued Patent Number 2020221280 to Anixa Biosciences for its breast cancer vaccine technology. The composition-of-matter patent provides exclusive protection in Australia through 2040. Technology is exclusively licensed from Cleveland Clinic with co-inventors from the institution. Expansion adds to Anixa's global IP estate in markets with rising breast cancer incidence.

Anixa Biosciences Q3 Results: EPS beats estimate, sales flat

Anixa Biosciences reported Q3 EPS of $(0.08), beating the $(0.09) estimate. Per-share losses widened 14.29% YoY from $(0.07) in the prior year quarter. Sales remained at $0.00, unchanged from the same period last year. The beat occurred despite a deeper absolute loss compared to the prior year.

Anixa Biosciences to present clinical updates at 2026 Cantor Fitzgerald conference

Anixa Biosciences to present at 2026 Cantor Fitzgerald Global Healthcare Conference. Presentation focuses on breast cancer vaccine and ovarian cancer CAR-T therapy. Breast cancer vaccine Phase 1 trial met endpoints with 74% immune response rate. Ovarian cancer therapy shows long-term survival up to 28 months in early cohorts.

Anixa Biosciences secures Australian patent for breast cancer vaccine

Anixa Biosciences, Inc. announced that IP Australia issued a Notice of Acceptance for a patent covering its breast cancer vaccine technology, licensed from Cleveland Clinic. The patent expands the company's global intellectual property portfolio, complementing existing protections in the US, Europe, China, and Japan. A Phase 1 trial funded by the U.S. Department of Defense showed the vaccine was safe and generated immune responses in over 74% of participants.